172 related articles for article (PubMed ID: 30799277)
21. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
[TBL] [Abstract][Full Text] [Related]
22. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes.
Cloyd JM; Ejaz A; Shen C; Dillhoff M; Williams TM; Noonan A; Pawlik TM; Tsung A
HPB (Oxford); 2020 Nov; 22(11):1569-1576. PubMed ID: 32063480
[TBL] [Abstract][Full Text] [Related]
23. Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I.
Vega EA; Kutlu OC; Salehi O; James D; Alarcon SV; Herrick B; Krishnan S; Kozyreva O; Conrad C
J Gastrointest Surg; 2020 Oct; 24(10):2409-2415. PubMed ID: 32394126
[TBL] [Abstract][Full Text] [Related]
24. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
25. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
[TBL] [Abstract][Full Text] [Related]
26. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first.
DiPeri TP; Newhook TE; Prakash LR; Ikoma N; Maxwell JE; Kim MP; Lee JE; Katz MHG; Tzeng CD
J Surg Oncol; 2022 Nov; 126(6):1021-1027. PubMed ID: 35726394
[TBL] [Abstract][Full Text] [Related]
28. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
29. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy Versus Surgery First Approach.
Hyman DW; Almerey T; Mujkanovic A; Hammons I; Tice M; Stauffer JA
Am Surg; 2022 Aug; 88(8):1868-1874. PubMed ID: 35465681
[TBL] [Abstract][Full Text] [Related]
30. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer.
Bergquist JR; Thiels CA; Shubert CR; Ivanics T; Habermann EB; Vege SS; Grotz TE; Cleary SP; Smoot RL; Kendrick ML; Nagorney DM; Truty MJ
Cancer Med; 2021 Sep; 10(17):5925-5935. PubMed ID: 34289264
[TBL] [Abstract][Full Text] [Related]
31. Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma.
Cloyd JM; Shen C; Santry H; Bridges J; Dillhoff M; Ejaz A; Pawlik TM; Tsung A
J Natl Compr Canc Netw; 2020 May; 18(5):556-563. PubMed ID: 32380462
[TBL] [Abstract][Full Text] [Related]
32. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma.
Pu N; Yin L; Habib JR; Gao S; Hu H; Zhu Y; Wu Y; Yu J; Lou W
Future Oncol; 2019 Oct; 15(30):3457-3465. PubMed ID: 31460788
[No Abstract] [Full Text] [Related]
33. Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma.
Shi S; Hua J; Liang C; Meng Q; Liang D; Xu J; Ni Q; Yu X
Ann Surg; 2019 May; 269(5):944-950. PubMed ID: 29334560
[TBL] [Abstract][Full Text] [Related]
34. Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
Rieser CJ; Zenati M; Narayanan S; Bahary N; Lee KK; Paniccia A; Bartlett DL; Zureikat AH
Ann Surg Oncol; 2021 Oct; 28(11):6264-6272. PubMed ID: 33748894
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.
Saka B; Balci S; Basturk O; Bagci P; Postlewait LM; Maithel S; Knight J; El-Rayes B; Kooby D; Sarmiento J; Muraki T; Oliva I; Bandyopadhyay S; Akkas G; Goodman M; Reid MD; Krasinskas A; Everett R; Adsay V
Ann Surg Oncol; 2016 Jun; 23(6):2010-8. PubMed ID: 26832882
[TBL] [Abstract][Full Text] [Related]
36. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma.
Cloyd JM; Prakash L; Vauthey JN; Aloia TA; Chun YS; Tzeng CW; Kim MP; Lee JE; Katz MHG
Am J Surg; 2019 Jul; 218(1):145-150. PubMed ID: 30224070
[TBL] [Abstract][Full Text] [Related]
37. The diversity between curatively resected pancreatic head and body-tail cancers based on the 8th edition of AJCC staging system: a multicenter cohort study.
Sheng W; Dong M; Wang G; Shi X; Gao W; Wang K; Song H; Shi G; Tan X
BMC Cancer; 2019 Oct; 19(1):981. PubMed ID: 31640615
[TBL] [Abstract][Full Text] [Related]
38. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
39. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome.
Das R; McGrath K; Seiser N; Smith K; Uttam S; Brand RE; Fasanella KE; Khalid A; Chennat JS; Sarkaria S; Singh H; Slivka A; Zeh HJ; Zureikat AH; Hogg ME; Lee KK; Paniccia A; Ongchin MC; Pingpank JF; Boone BA; Dasyam AK; Bahary N; Gorantla VC; Rhee JC; Thomas R; Ellsworth S; Landau MS; Ohori NP; Henn P; Shyu S; Theisen BK; Singhi AD
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):886-897. PubMed ID: 33278573
[TBL] [Abstract][Full Text] [Related]
40. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
